Ranisan 75 mg
Basic information
Composition
Ranitidine hydrochloride 84 mg in 1 coated tablet
Pharmacotherapeutic group
H2-receptor antagonists (ATC code: A02BA02)
Therapeutic indications
Short and symptomatic treatment of the signs of heartburn, gastric hyperacidity and nausea.
Pharmacological properties
Ranitidine, a histamine H2-receptor antagonist, inhibits diurnal and nocturnal gastric secretion, both basal and stimulated, thus causing a decrease in the acidity and volume of gastric juice. If administered orally, ranitidine is absorbed very rapidly and the maximum plasma level is reached within 1–3 hours. The food does not affect the biological availability of ranitidine. Biological half-life ranges between 2–3 hours, in renal insufficiency it is prolonged.
Pharmaceutical form
Film-coated tabletsMore information
Posology and method of administration
One tablet is taken in case of problems; two tablets may be taken over a 24-hour period. Total duration of treatment without consulting a physician should not exceed 5 days. Tablets are taken unchewed, with or without food and with plenty of fluids.
Contraindications
Hypersensitivity to ranitidine or the excipients. Administer to pregnant and breast-feeding women only if clearly needed.
Interactions
Ranitidine influences cytochrome P-450 so slightly, practically no drug interactions on this basis occur. By reducing the acidity of the contents of the stomach, ranitidine may reduce ketoconazole absorption. Concomitant administration of ranitidine with high doses of sucralfate (2 g) may reduce ranitidine absorption.
Undesirable effects
The following may appear: headache, dizziness, confusion in elderly people, nausea, constipation, diarrhoea, blurred vision, impotence, hair loss, allergic skin reactions, raised levels of liver enzymes, leukocytopenia and thrombocytopenia. In very rare cases, heart rhythm disorders were reported.
Special warnings and precautions for use
Before starting treatment, malignancy of the gastric ulcer must be ruled out.
Availability
Contents of container
10 tablets
Package available in the Czech Republic
10 tablets
SPC and PIL
Detailed information
For more detailed product information, see the Summary of Product Characteristics.
Manufacturer and marketing authorisation holder
Date of revision of the text
3 May 2019Product images
